Table 3.
Association of the 2-year overall survival and disease-free survival with different clinicopathological variables and biomarkers
| 2-year overall survival (OS) (%) | p value | 2-year disease-free survival (DSF) (%) | p value | |
|---|---|---|---|---|
| Gender | ||||
| Male | 89.5 | 0.00* | 73.7 | 0.00* |
| Female | 0 | 0 | ||
| T stage | ||||
| T2 | 100 | 0.541 | 33.3 | 0.18 |
| T3 | 100 | 50 | ||
| T4 | 75 | 75 | ||
| N stage | ||||
| N0 | 100 | 0.738 | 100 | 0.422 |
| N1 | 75 | 50 | ||
| N2 | 81.8 | 72.7 | ||
| Skin involvement | ||||
| Present | 100 | 0.242 | 100 | 0.095 |
| Absent | 75 | 56.2 | ||
| Bone involvement | ||||
| Present | 90 | 0.282 | 90 | 0.023* |
| Absent | 72.7 | 45.5 | ||
| GADD45 | ||||
| 0 | 0 | 0.005* | 0 | 0.012* |
| 1 | 100 | 100 | ||
| 2 | 83.3 | 58.3 | ||
| 3 | 100 | 100 | ||
| HPV status | ||||
| Positive | 100 | 0.234 | 100 | 0.077** |
| Negative | 75 | 56.2 | ||
| EGFR grading | ||||
| 1 | 83.3 | 0.566 | 83.3 | 0.518 |
| 2 | 60 | 40 | ||
| 3 | 90 | 70 | ||
| Her-2-neu | ||||
| Positive | 100 | 0.392 | 66.7 | 0.933 |
| Negative | 77.8 | 66.7 | ||
| Pathological lymph node involvement | ||||
| Present | 81.8 | 0.899 | 63.7 | 0.47 |
| Absent | 80 | 70 | ||
| Vascular invasion | ||||
| Present | 71.4 | 0.273 | 66.7 | 0.86 |
| Absent | 88.9 | 71.4 | ||
| Perineural invasion | ||||
| Present | 57.1 | 0.05* | 57.1 | 0.36 |
| Absent | 100 | 77.8 | ||
| Lymphatic invasion | ||||
| Present | 71.4 | 0.273 | 66.7 | 0.86 |
| Absent | 88.9 | 71.4 | ||
*statistically significant; **approaching statistical significance